News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
FDA Advisory Panel Votes Against Drug Combination Phentermine / Topiramate for Weight Loss
July 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GAITHERSBURG, Md. — A Food and Drug Administration advisory panel voted 10 to 6 against recommending approval of a combination of phentermine and topiramate as a weight loss agent because of concerns over the treatment’s risk-benefit profile.
Twitter
LinkedIn
Facebook
Email
Print